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Objective: Megestrol acetate oral suspension (MAOS) is an appetite stimulant indicated for 
cachexia in patients with AIDS. It is available in its original formulation, Megace® (MAOS), and 
as a nanocrystal dispersion, Megace® ES (MA-ES). Three studies were conducted to evaluate 
the pharmacokinetic properties of these formulations under fed and fasting conditions.
Methods: An open-label, crossover trial was conducted in 24 healthy males randomized to 
MA-ES 625 mg/5 mL given with a high-calorie, high-fat meal, or after an overnight fast. Blood 
samples were drawn at multiple time points and pharmacokinetic parameters were determined. 
Two separate, open-label reference studies evaluated MAOS 800 mg/20 mL in 40 fed or 
40 fasting healthy male volunteers.
Results: In fasting MA-ES subjects, the average maximum concentration (Cmax) was 30% less 
than the fed Cmax value. For MAOS, fasting Cmax was 86% less than fed Cmax. In fasting subjects, 
the area under the curve was 12,095 ng⋅h/mL for MA-ES, and 8,942 ng⋅h/mL for MAOS. In fed 
subjects, the absorption of the two formulations was comparable.
Conclusion: Bioavailability and absorption are greater for MA-ES than MAOS in fasting 
subjects. MA-ES may be a preferred formulation of megestrol acetate when managing cachectic 
patients whose caloric intake is reduced.
Keywords: megestrol acetate, bioavailability, cachexia, nanocrystal technology, appetite 
stimulant
Introduction
Nutritional status affects health, disease state outcomes, and quality of life.1,2 Inadequate 
food intake that does not meet metabolic and caloric demands can lead to unintended 
weight loss (UWL), a distinguishing clinical feature of cachexia.3 Cachexia or wasting 
disease is associated with underlying illness such as AIDS, cancer, heart failure, 
kidney failure, COPD, or rheumatoid arthritis,4 and is distinct from conditions such as 
starvation, malabsorption, age-related loss of muscle mass, or hyperparathyroidism.3 
As many as 5 million people in the United States, or 20% to 40% of those affected 
with chronic conditions, may require treatment for cachexia.4 Among patients with 
AIDS, cachexia is a prevalent comorbidity, affecting up to 35% of AIDS patients in 
the United States.4 Diagnostic criteria for cachexia include UWL  5% in 12 months 
or less in the presence of underlying illness or body mass index (BMI)  20 kg/m2; 
additional criteria are described by Evans et al 2008.3
Megestrol acetate oral suspension (MAOS) is an orexigenic agent indicated for 
the treatment of anorexia, cachexia, or an unexplained, significant weight loss in 
patients with AIDS. The original formulation of MAOS (Megace®; Bristol-Myers International Journal of Nanomedicine 2009:4 186
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Squibb, Princeton, New Jersey, USA) is relatively more 
viscous than other liquid medications and the recommended 
dose of 800 mg/20 mL or 4 teaspoons,5 once daily may 
be limiting factors for patients with decreased appetite 
or difficulty swallowing. To improve the palatability of 
MAOS, nanocrystal technology (Elan Pharma Interna-
tional Limited, King of Prussia, Pennsylvania, USA) was 
applied to produce a nanocrystal dispersion6 of megestrol 
acetate (MA-ES; Megace® ES; Par Pharmaceutical, Inc., 
Spring Valley, New York, USA), which is a more concen-
trated suspension with improved dissolution and decreased 
viscosity.
An initial pharmacokinetic (PK) study demonstrated 
that MA-ES 625 mg/5 mL was bioequivalent to MAOS 
800 mg/20 mL under fed conditions;5 however, when PK 
parameters were analyzed under fasting conditions, MA-ES 
unexpectedly showed greater bioavailability than MAOS. 
Bioavailability, or the amount of drug available to provide 
a therapeutic response, is dependent on absorption.7 Since 
drug absorption and bioavailability under fasting condi-
tions are particularly relevant to patients with cachexia, 
studies to characterize the PK profiles of MA-ES and 
MAOS were undertaken. This paper describes results from 
three studies evaluating the food effect on bioavailability of 
MA-ES 625 mg/5 mL and MAOS 800 mg/20 mL in healthy 
individuals under fed and fasting conditions.
Methods
study 1: Open-label, randomized, two-way 
crossover study of MA-es 625 mg/5 mL
A prospective, randomized, open-label, two-way crossover 
study to evaluate the bioavailability of MA-ES under fed and 
fasting conditions was conducted in healthy male volunteers, 
18 to 55 years of age, with no clinically significant medical 
histories (Figure 1).
Subjects were screened up to 28 days prior to receiving 
treatment. Following screening, subjects were random-
ized to receive a single dose of MA-ES 625 mg/5 mL 
after an overnight fast of at least 10 hours, or immediately 
after eating a standard, high-calorie, high-fat meal of 
800 to 1000 calories consisting of 2 eggs fried in butter, 
2 slices of toast with butter, 2 strips of bacon, 4 oz of hash 
brown potatoes, and 8 oz of whole milk.8 The study drug 
was administered orally with the standard 8 oz of water. 
Following a 14-day washout period, subjects received a 
second single dose of MA-ES under the crossover (fed or 
fasting) condition.
Study 1
Randomized
(N = 24)
MA-ES 625 mg/5 mL
Feda Condition
(n = 13)
MA-ES 625 mg/5 mL
Fasting Condition
(n = 11)
MA-ES 625 mg/5 mL
Fed* Condition
(n = 11)
MA-ES 625 mg/5 mL
Fasting Condition
(n = 12)
withdrawn (n = 1)
Study 2
Enrolled
(N = 40)
MAOS 800 mg/20 mL
Feda Condition
(n = 40)
withdrawn (n = 8)
Study 3
Enrolled
(N = 40)
Evaluable
(N = 36)
Evaluable
(N = 23)
Evaluable
(N = 32)
MAOS 800 mg/20 mL
Fasting Condition
(n = 40)
withdrawn (n = 4)
Figure 1 Flow diagrams for pharmacokinetic studies of a nanocrystal dispersion of megestrol acetate (MA-es) 625 mg/5 mL and a micronized formulation of  megestrol  acetate 
oral suspension (MAOs) 800 mg/20 mL in fed and fasting subjects.
Note:  a800 to 1000 calories, ∼50% fat.International Journal of Nanomedicine 2009:4 187
Megestrol acetate oral suspension bioavailability Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
During each treatment period, subjects remained at the 
study site for at least 10 hours pre-dose through 24 hours 
post-dose, after which they were discharged but returned at 
specified times for blood sample collection up to 120 hours 
post-dose. Plasma concentrations of megestrol acetate were 
quantified by a validated liquid chromatography, tandem 
mass spectrometric method. The lower limit of quantification 
was 2 ng/mL.
Bioequiv (release 3.50) proprietary software (SFBC 
Anapharm, Sainte-Foy, Quebec, Canada) was used to 
calculate the following PK parameters: area under the plasma 
concentration-time curve (AUC) from time 0 to the time of  the 
last non-zero concentration of the study drug (AUC0–t); AUC 
from time 0 to infinity (AUC0–∞); maximum observed plasma 
concentration (Cmax); time to Cmax (tmax); and elimination half-life 
(t1/2). Descriptive statistics were tabulated by treatment for all 
PK parameters, as applicable. For AUC0–t, AUC0–∞, and Cmax, 
analysis of variance (SAS General Linear Models procedure) 
was used to compare logarithmic-transformed (base) values 
from the fed and fasting treatments. This model includes 
sequence, subject within sequence, study period, and treatment 
as factors. The 90% confidence intervals (CI) were estimated 
for the ratio (fed/fasting) of least-squares means (LSM).
Vital signs, electrocardiograms (ECG), and clinical 
laboratory parameters (hematology, blood chemistry, and 
urinalysis) were monitored, and adverse events were recorded 
throughout the study.
studies 2 and 3: Open-label studies  
of MAOs 800 mg/20 mL in fed and fasting 
subjects9 (Figure 1)
An open-label study to assess the bioavailability of MAOS 
under fed conditions (Study 2) was performed in healthy 
males at least 18 years of age, with no clinically significant 
medical histories. Subjects received a single, 800 mg/20 mL 
dose of MAOS within 30 minutes of consuming a standard 
high-calorie, high-fat meal as described previously.8 Blood 
samples were collected pre-dose, then sequentially for up 
to 96 hours post-dose. Plasma concentrations of megestrol 
acetate were measured by liquid chromatography with tan-
dem mass spectrometry detection, and PK parameters (Cmax, 
tmax, AUC0–t, AUC0–∞, and t1/2) were determined. Any adverse 
events reported throughout the study period were recorded.
An open-label study to assess the bioavailability of 
MAOS under fasting conditions (Study 3) was similarly 
performed in healthy males, at least 18 years of age, with 
no clinically significant medical histories. Subjects received 
a single, 800 mg/20 mL dose of MAOS after an overnight 
fast of at least 10 hours. The protocol for blood sampling 
and plasma concentration measurement was identical to 
the fed study, and the same PK parameters were evaluated. 
Adverse events reported throughout the study period were 
recorded.
All three studies received Institutional Review Board 
approval, and were conducted in accordance with Good 
Clinical Practice guidelines as required by the Declaration of 
Helsinki. All subjects provided written, informed consent.
Results
study 1: Open-label, randomized, two-way 
crossover study with MA-es 625 mg/5 mL
A total of 24 subjects were randomized to the study; the 
analysis population included 23 subjects. One subject who 
did not follow protocol and received treatment under the 
wrong condition was discontinued from the study. Megestrol 
acetate plasma concentrations were zero in all subjects prior 
to dosing in both study periods.
The PK parameters for MA-ES 625 mg/5 mL administered 
under fed and fasting conditions are shown in Table 1. 
AUC0–∞ decreased from 16,268 ng⋅h/mL in the fed state 
to 12,095 ng⋅h/mL in the fasting state. The mean Cmax 
decreased from 1,618 ng/mL in the fed to 1,133 ng/mL in 
the fasting state. Absorption of MA-ES based on AUC and 
Cmax showed a decrease of 26% and 30%, respectively, in the 
fasting compared with the fed state. The fed to fasting ratios 
(90% CI) of least-squares means for AUC0–t, AUC0–∞, and 
Cmax, were 1.36 (1.26 to 1.47), 1.36 (1.26 to 1.47), and 1.48 
(1.28 to 1.71), respectively, indicating that consumption of 
a high-fat meal increased the rate and extent of absorption 
of MA-ES. Figure 2 shows the profile for mean plasma 
concentration over time for MA-ES administered under fed 
or fasting conditions.
All 24 subjects were included in the safety population. 
The drug was well tolerated under both fed and fasting 
conditions. There were no deaths, serious adverse events or 
other clinically relevant adverse events. Table 2 shows the 
9 treatment-emergent adverse events that were reported. 
Each adverse event was reported once, except for increased 
blood pressure, which was reported in 2 subjects. All adverse 
events were mild to moderate in intensity, except for an 
incident of severe vomiting reported by 1 patient during the 
fed condition of the crossover treatment. The frequency and 
severity of adverse events were similar under fed and fasting 
conditions, and the majority of adverse events had resolved 
spontaneously by the end of the study. Changes in ECGs, International Journal of Nanomedicine 2009:4 188
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clinical laboratory values, and vital signs were unremarkable 
and not considered related to therapy.
studies 2 and 3: Open-label studies 
of MAOs 800 mg/20 mL in fed  
and fasting subjects
In study 2, 40 healthy volunteers were enrolled to evaluate 
MAOS bioavailability under fed conditions. Six subjects had 
protocol deviations and withdrew prior to study completion. 
One subject withdrew due to clinically significant hematology 
results, and another subject withdrew due to diarrhea. A total 
of  32 subjects provided evaluable data. Study 3 also enrolled 
40 healthy male subjects, who were evaluated for MAOS 
bioavailability under fasting conditions. Four subjects 
were not included in the statistical analysis due to protocol 
deviations resulting in 36 subjects with evaluable data.
The PK parameters for an 800 mg/20 mL dose of MAOS 
given under fed or fasting conditions are summarized in 
Table 1. In the fed state, AUC0–∞ was 18,625 ng⋅h/L and the 
mean Cmax was 1,364 ng/mL. In the fasting state, AUC0–∞ only 
reached 8,942 ng⋅h/L with a Cmax of 187 ng/mL. Relative to the 
fed state, AUC0–∞ and Cmax were decreased by 52% and 86%, 
respectively, in the fasting state. The mean plasma concentra-
tion-time profiles for MAOS after administration of a high-fat 
meal and during a fasting state are shown in Figure 3.
For the 32 subjects included in the safety population of 
the study conducted under fed conditions, adverse events 
were generally mild or moderate in severity. There was 
1 unrelated severe adverse event of vomiting, 13 days 
post-dose. No serious adverse events were reported, and all 
adverse events were considered unlikely to be related to the 
study medication. For the 36 subjects included in the safety 
population of the study conducted under fasting conditions, 
Table 1 Mean (sD) pharmacokinetic parameters for a nanocrystal dispersion of megestrol acetate (MA-es) 625 mg/5 mL and a micronized 
formulation of megestrol acetate oral suspension (MAOs) 800 mg/20 mL administered in a fed or fasting state
Parameter MA-ES 625 mg/5 mL MAOS 800 mg/20 mL
Study 1 (N = 23) Study 2 (N = 32) Study 3 (N = 36)
Fed Fasting Fed Fasting
AUc0–t (ng ⋅ h/mL) 15,287 (4,646) 11,301 (3,583) 16,757 (4,670) 7,011 (4,704)
AUc0–∞ (ng ⋅ h/mL) 16,268 (5,174) 12,095 (4,111) 18,625 (5,907) 8,942 (8,934)
cmax (ng/mL) 1,618 (438) 1,133 (429) 1,364 (387) 187 (107)
tmax (h) 2.91 (1.88) 1.72 (1.42) 3.85 (0.89) 5.89 (6.32)
t½ (h) 39.75 (10.79) 33.68 (9.02) 32.84 (9.00) 31.38 (18.74)
Abbreviations:   AUc, area under the curve; cmax, maximum plasma concentration; sD, standard deviation; tmax, time to maximum concentration; t1/2, half-life.
Time (h)
P
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
0
200
400
600
800
1000
1200
1400
MA-ES 625 mg/5 mL (fed)
MA-ES 625 mg/5 mL (fasting)
0 12 24 36 48 60 72 84 96 108 120
Figure 2 Mean plasma concentration profilea for a nanocrystal dispersion of megestrol acetate (MA-es) 625 mg/5 mL in fed and fasting states (N = 23).
Data from study 1.
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adverse events were mild or moderate in severity. No serious, 
severe, or significant adverse events were reported.
Food effect on bioavailability of MA-es 
and MAOs
As shown in Figure 4, single doses of MA-ES 625 mg/5 mL 
and MAOS 800 mg/20 mL have comparable bioavailability 
under fed conditions, but under fasting conditions the 
bioavailability of MA-ES is greater than that of MAOS.
Discussion
Bioequivalence of MA-ES 625 mg/5 mL to MAOS 
800 mg/20 mL is seen under fed conditions; however, the 
bioavailability of a poorly water soluble10 lipophilic drug, 
such as megestrol acetate,11 is greatly impacted under fasting 
conditions.
Drugs with poor water-solubility are frequently 
associated with highly variable absorption based upon food 
intake.10 The enhanced bioavailability of MAOS when taken 
with a high-fat meal is predictable, as the lipophilic drug 
dissolves readily in the fat content of food. In the fasting 
state, MAOS demonstrates poor bioavailability, probably 
due to its poor water solubility, which contributes to reduced 
dissolution. The change in the absorption profile of MAOS 
between fed and fasting states had not been character-
ized when the drug was initially approved for marketing 
in 1993.
Solubility, and thus absorption and bioavailability, of 
lipophilic drug molecules can be improved with a reduction 
in particle size to submicron levels.12 To improve the 
solubility of megestrol acetate, nanocrystal technology was 
applied to the original formulation to reduce the drug particle 
size to 80 to 400 nm in diameter (up to 50 times smaller 
than the micronized particles in MAOS), thus increasing the 
total surface area of drug particles and improving dissolution 
of MA-ES. When the PK data for MA-ES was compared 
to that of MAOS, the difference between drug absorption 
of the two formulations under fasting conditions became 
apparent.
Results from the current studies demonstrate that Cmax 
and total absorption (AUC0–∞) of MAOS are markedly 
reduced (by 86% and 52%, respectively) in fasting 
Table 2 Incidence of adverse events following a single dose of a 
nanocrystal dispersion of megestrol acetate (MA-es) 625 mg/5 mL 
(study 1)
Fed (N = 24) 
n (%)
Fasting (N = 23) 
n (%)
Patients with at least one Ae 3 (12.5%) 4 (17.4%)
Blood glucose increased 1 (4.2%) 0 (0.0)
skin exfoliation 1 (4.2%) 0 (0.0)
Vomiting 1 (4.2%) 0 (0.0)
Blood pressure increased 0 (0.0) 2 (8.7%)
headache 0 (0.0) 1 (4.3%)
heart rate increased 0 (0.0) 1 (4.3%)
Palpitations 0 (0.0) 1 (4.3%)
Protein urine 0 (0.0) 1 (4.3%)
8
0
200
400
600
800
1000
1200
1400
MAOS 800 mg/20 mL (fasting)
MAOS 800 mg/20 mL (fed)
Time (h)
M
e
a
n
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
96 92 88 84 80 76 72 68 64 60 56 52 48 44 40 36 32 28 24 4 0 12 16 20
Figure 3 Mean plasma concentration profilea for a micronized formulation of megestrol  acetate oral suspension (MAOs) 800 mg/20 mL in fed and fasting states.
Data from study 2, MAOs in fed (N = 32) subjects, and study 3, MAOs in fasting (N = 36) subjects.
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versus fed subjects. Since cachectic patients can have 
minimal appetite, and are often in the fasted state, the poor 
bioavailability of MAOS in this state may be a significant 
impediment. Graham et al report in their 21-day study 
of AIDS patients with cachexia that there is a significant 
correlation between sustained plasma concentrations 
of MAOS above a threshold of 300 ng/mL and weight 
gain.13 Patients in the study were administered MAOS 
800 mg/20 mL, once daily, prior to breakfast. We report 
a Cmax value of 187 ng/mL for MAOS in the fasting 
state, which is below the 300 ng/mL threshold suggested 
for weight gain to occur.
Cmax and total absorption of MA-ES in fasting versus 
fed subjects are reduced by much smaller margins (30% 
and 26%, respectively). Since absorption of MA-ES is less 
profoundly affected by the presence or absence of food, this 
formulation may offer potential clinical benefit for cachectic 
patients with impaired appetite and low caloric intake. 
HIV-positive patients (n = 63) with 10% unintended weight 
loss were randomized to once daily treatment with MA-ES 
575 mg/5 mL or MAOS 800 mg/20 mL for 12 weeks.14 
Although MA-ES 575 mg/5 mL is not an FDA-approved 
dose, it is formulated using nanocrystal technology. Patients 
receiving MA-ES 575 mg/5 mL showed statistically signifi-
cant weight gain from baseline as early as week 1. At the end 
of 12 weeks patients gained an average of 10% (11.9 lbs; 
5.4 kg) of their baseline weight, which was statistically 
significant (P  0.05). In addition, weight gain from base-
line during the study was statistically significant at several 
time points. Patients receiving MAOS did not show weight 
gain until week 2. At the end of 12 weeks, patients gained 
an average of 6% (7.7 lbs; 3.5 kg) of their baseline weight, 
but weight gain was not statistically significant at any time 
point from baseline.
At study end, MA-ES 575 mg/5 mL patients did gain 
the 10% weight they had lost at baseline, and weight gain 
occurred more rapidly at each time point than for MA-OS. 
The difference in weight gain results between MA-ES 
575 mg/5 mL and MA-OS may be due to the improved 
absorption of the MA-ES formulation in people who have 
not eaten, although this study was not controlled for food 
or caloric intake. Most studies evaluating orexigenic agents 
for treatment of unintended weight loss are 12 weeks in 
duration.15–18 The improved bioavailability of MA-ES 
may facilitate earlier weight gain, and potentially shorten 
treatment duration.
The MA-ES formulation is associated with other 
properties that may be important to patients or caregivers. 
Since the MA-ES formulation is more concentrated 
at 125 mg/mL than MAOS, which is 40 mg/mL, the 
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recommended dose of MA-ES is delivered in a smaller 
volume of 5 mL (1 teaspoonful), once daily; whereas, the 
recommended dose of MAOS is 20 mL (4 teaspoonsful), 
once daily.19 The reduction in megestrol acetate particle size 
in the MA-ES formulation also resulted in a suspension that 
is much less viscous than MAOS (10 centipoise versus 163 
centipoise, respectively [data on file, Par Pharmaceutical, 
Inc., Spring Valley, New York, USA]). These factors may 
make MA-ES more palatable for patients who lack appetite 
and/or may have difficulty swallowing.
Although MAOS and MA-ES contain the same active 
ingredient, they are not considered therapeutic equivalents20 
because of the differences in concentration and fasting 
bioavailability between each drug.
The PK profile for MAOS under fed and fasted 
conditions (Study 2 and Study 3) was needed for the MA-ES 
New Drug Application submitted to the FDA. FDA approval 
was based on bioequivalence of MA-ES to MAOS under fed 
conditions. Subsequently, Study 1 was conducted to further 
characterize the food-effect bioavailability of MA-ES. 
Since the PK profile for MAOS was already established, the 
results were evaluated relative to the PK profile of MA-ES 
from Study 1. Although these 3 PK studies described in the 
current report were conducted in a similar manner among 
healthy male subjects, the potential for differences between 
the study populations, assays, and sampling techniques 
cannot be discounted. Thus, any comparison of data across 
studies should be undertaken carefully. These studies are 
also limited by the absence of female subjects from the 
study populations.
A further limitation of these studies is that PK parameters 
in healthy volunteers may not be generalizable to cachectic 
patients, who suffer from underlying disease, take 
concomitant medications, and may be elderly. Studies 
evaluating food effects and the effect of variable caloric 
intake on the bioavailability of MA-ES and MAOS, and 
correlation with clinical improvement in patients with 
cachexia would be of interest.
Conclusions
Food intake has the potential to affect drug absorption and 
bioavailability. This is a particularly important consider-
ation when treating patients with cachexia or UWL because 
they often have low caloric intake. MA-ES is an improved 
formulation that is more readily absorbed and has improved 
bioavailability in the fasting state as compared to the original 
megestrol acetate oral suspension.
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